Observational studyEmerging microbes & infections2019
Isolation of group B Streptococcus with reduced β-lactam susceptibility from pregnant women.
Observational study in Emerging microbes & infections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Global trends in macrolide and lincosamide resistance in Streptococcus species: a comprehensive systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Global patterns of antibiotic resistance in group BFrontiers in microbiology · 2025Pooled it
- Gene Factors and Serotypes Related to Polysaccharide and Protein-Based Candidate Vaccines AmongCurrent issues in molecular biology · 2026Article
- Group B Streptococcus colonization, antibiotic resistance, and maternal-neonatal outcomes in late pregnancy: a retrospective study from 2017 to 2024.BMC pregnancy and childbirth · 2026Article
- Dairy FarmPathogens (Basel, Switzerland) · 2026Article
- Characterization of Penicillin-Non-Susceptible, Multidrug-Resistant Streptococcus agalactiae Using Whole-Genome Sequencing.Current microbiology · 2025Article
- Genomic Diversity, Virulome, and Resistome ofPathogens (Basel, Switzerland) · 2025Article
- Endolysin EN572-5 as an alternative to treat urinary tract infection caused by Streptococcus agalactiae.Applied microbiology and biotechnology · 2024Article
- Molecular Serotyping and Antibiotic Resistance Profile of Group BIranian journal of medical sciences · 2023Article
- Cost-effectiveness analysis of maternal vaccination against Group B streptococcus in Japan.Vaccine: X · 2023Article
- Characteristics ofIranian journal of basic medical sciences · 2023Article
- Epidemiology and bacterial characteristics of invasive group B streptococcus disease: a population-based study in Japan in 2010-2020.Epidemiology and infection · 2022Article
- Macrolide-resistance, capsular genotyping and associated factors of group B Streptococci colonized pregnant women in Isfahan, Iran.Iranian journal of microbiology · 2021Article
- Multistate, Population-Based Distributions of Candidate Vaccine Targets, Clonal Complexes, and Resistance Features of Invasive Group B Streptococci Within the United States, 2015-2017.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Efficient Inhibition ofFrontiers in chemistry · 2021Article
- Streptococcus agalactiae in pregnant women: serotype and antimicrobial susceptibility patterns over five years in Eastern Sicily (Italy).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Group B streptococcal disease in the mother and newborn-A review.European journal of obstetrics, gynecology, and reproductive biology · 2020Article
- Multidrug-ResistantMicroorganisms · 2020Article
- Increasing Resistance and Changes in Distribution of Serotypes ofPathogens (Basel, Switzerland) · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Lactam antibiotics are first-line agents for the treatment and prevention of group B Streptococcus (GBS) infections. We previously reported clinical GBS isolates with reduced β-lactam susceptibility (GBS-RBS) and characterized them as harbouring amino acid substitutions in penicillin-binding proteins (PBPs). However, to our knowledge, GBS-RBS clinical isolates have never previously been isolated from pregnant women worldwide. We obtained 477 clinical GBS isolates from vaginal/rectal swabs of 4530 pregnant women in Japan. We determined the MICs of seven β-lactams for all 477 clinical isolates. Five clinical isolates showed reduced ceftibuten susceptibility. For these isolates, we performed sequencing analysis of pbp genes. None of the 477 isolates were non-susceptible to penicillin G, ampicillin, and meropenem. For five isolates, the MICs of ceftibuten were relatively high (64-128 μg/ml). Each of these isolates possessed a single amino acid substitution in PBP2X, and some of the substitutions had been previously found in GBS with reduced penicillin susceptibility. This is the first report of the isolation of clinical GBS-RBS isolates harbouring amino acid substitutions in PBP2X that confer reduced ceftibuten susceptibility from pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.